Novel Laboratories leverages its technological capabilities and formulation expertise to develop niche pharmaceutical products. Novel continues to expand its technological capabilities into more dosage forms and delivery systems. Our global manufacturing capabilities – which includes a range of over 40 dosage forms and delivery systems – gives us the capacity to produce over one billion doses per year. We continue to keep a tight focus on quality systems designed to ensure consistent compliance and reliable manufacturing processes for our clients.
With 30 product approvals, more than 90 filed ANDAs, 8 first-to-file submissions and 16 confirmed Paragraph IVs, Novel is positioned to deliver a continuous stream of important new products over the next decade. This potential is further enhanced by strategic R&D and an aggressive product development program focused on hard-to formulate and difficult-to-manufacture products that span a range of dosage forms, including sprays, inhalers, injectables, MDIs, and ophthalmics, just to name a few.